DÄ internationalArchive44/2007Secondary Stroke Prevention

Review article

Secondary Stroke Prevention

Recent Advances

Dtsch Arztebl 2007; 104(44): A-3016

Diener, H; Grond, M; Böhm, M; Eckstein, H; Forsting, M

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Diener HC, Allenberg J-R, Bode C et al.: Leitlinien der Deutschen Gesellschaft für Neurologie und der Deutschen Schlaganfallgesellschaft zur Primär- und Sekundärprävention des Schlaganfalls: Aktualisierung 2006. Akt Neurol 2007; 34: 8–12.
2. Sacco RL, Adams R, Albers G et al.: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006; 113: e409–49. MEDLINE
3. Progress Collaborative Group: Randomised trial of a perindopril-based blood-pressure lowering regimen among 6 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41. MEDLINE
4. Dahlof B, Devereux RB, Kjeldsen SE et al.: Cardiovascular morbidity and mortality in the lorsartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003. MEDLINE
5. Schrader J, Luders S, Kulschewski A et al.: Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218–26. MEDLINE
6. Diener HC, Sacco R, Yusuf S, for the Steering Committee and PRoFESS Study Group: Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens and telmisartan vs. placebo in patients with strokes: the prevention regimen for effectively avoiding second strokes (PRoFESS) trial. Cerebrovasc Dis 2007; 23: 368–80. MEDLINE
7. Amarenco P, Lavallee P, Touboul PJ: Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004; 3: 271–8. MEDLINE
8. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22. MEDLINE
9. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59. MEDLINE
10. Amarenco P, Labreuche J, Lavallee P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35: 2902–9. MEDLINE
11. Diener HC, Cuhna L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13. MEDLINE
12. The ESPRIT Study Group: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006; 367: 1665–73. MEDLINE
13. The Esprit Study Group: Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet Neurol 2007; 6: 115–24. MEDLINE MEDLINE
14. CAPRIE Steering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39. MEDLINE
15. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502. MEDLINE
16. Diener HC, Bogousslavsky J, Brass L et al.: Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomized after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results. Lancet 2004; 364: 331–4. MEDLINE
17. Bhatt DL, Fox KA, Hacke W et al.: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–17. MEDLINE
18. EAFT Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62. MEDLINE
19. ACTIVE Writing Group on behalf of the ACTIVE Investigators, Connolly S, Pogue J et al.: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006; 367: 1903–12. MEDLINE
20. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 231–3. MEDLINE
21. Ringleb PA, Allenberg J, Bruckmann H et al.: 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomized non inferiority trial. Lancet 2006; 368: 1239–47. MEDLINE
22. Mas JL, Chatellier G, Beyssen B et al.: Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355: 1660–71. MEDLINE